other material
confidence high
sentiment positive
materiality 0.70
JAGX stockholders approve three proposals; crofelemer MVID trial shows up to 37% PS reduction
Jaguar Health, Inc.
- Stockholders approved proposal to issue shares upon exchange/redemption of Series N Preferred Stock (1,032,716 For, 73,065 Against).
- Stockholders approved proposal to issue New PIPE Shares and Pre-Funded Warrant under Sept 28 securities purchase agreement (2,049,724 For).
- Stockholders approved adjournment proposal (2,058,277 For).
- Initial MVID proof-of-concept trial shows crofelemer can reduce total parenteral support by up to 37% in infants with microvillus inclusion disease.
- Company met with FDA on Oct 2, 2025 for advice on expedited approval pathway for crofelemer for MVID; no approved treatments exist.